[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369639-105":59,"doc-detail-369639-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","post-authorisation-safety-study-to-assess-the-risk-of-urinary-tract-cancer-in-people-with-type-2-diabetes-initiating-empagliflozin-a-multi-country-european-study","Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin - A multi-country European study","","Aims: Assess urinary tract cancer risk, including bladder and renal cancers, in type 2 diabetes patients initiating empagliflozin versus initiation of any DPP-4 inhibitor in the UK, Sweden, and Finland. Materials and Methods: Non-interventional multi-country cohort using secondary data with an active comparator, propensity score matching, and an as-treated approach; latency was 180 days. Results: Meta-analysis across countries showed no increased risk for urinary tract, bladder, or renal cancer; sensitivity analyses supported robustness. Conclusions: No increased cancer risk was observed for empagliflozin versus DPP-4 inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/post-authorisation-safety-study-to-assess-the-risk-of-urinary-tract-cancer-in-people-with-type-2-diabetes-initiating-empagliflozin-a-multi-country-european-study/369639/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/post-authorisation-safety-study-to-assess-the-risk-of-urinary-tract-cancer-in-people-with-type-2-diabetes-initiating-empagliflozin-a-multi-country-european-study/369639.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary objective of the post-authorisation safety study?","Question",{"text":112,"@type":113},"To assess whether people with type 2 diabetes initiating empagliflozin had a different risk of urinary tract cancers, including bladder and renal cancers, compared with those initiating any DPP-4 inhibitor in the UK, Sweden, and Finland.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and what data sources were used?",{"text":117,"@type":113},"It was a non-interventional, multi-country cohort PASS using secondary data: CPRD in the UK and nationwide registers in Sweden and Finland, with an active comparator and a new user design using propensity score matching.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding cancer risk?",{"text":121,"@type":113},"The meta-analysis showed no evidence of increased risk of urinary tract cancer, bladder cancer, or renal cancer for empagliflozin initiators versus DPP-4 inhibitor initiators, and sensitivity analyses validated the robustness of these findings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369639,1790881263,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","DOI: 10.1111/dom.16477  \nO R IG INA L ARTI CLE  \nPost-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study  \nNiklas Schmedt PhD 1  | Ayman Alhamdow PhD 1  | Giorgi Tskhvarashvili MSc 2  | Laura Saarelainen PhD 3  | Xu Qiao MSc 3  | Muriel Lobier PhD 3  |  \nFabian Hoti PhD 3   \n1Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany  \n2IQVIA, Tallinn, Estonia 3IQVIA, Espoo, Finland  \nCorrespondence  \nFabian Hoti, IQVIA, Espoo, Finland.  \nEmail: [fabian.hoti@iqvia.com](fabian.hoti@iqvia.com)  \nFunding information  \nBoehringer Ingelheim & Eli Lilly; Company Diabetes Alliance  \nAbstract  \nAims: This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase-4 inhibitor (DPP-4i) in the United Kingdom (UK), Sweden, and Finland.  \nMaterials and Methods: This was a non-interventional, multi-country cohort study based on secondary data in Sweden, Finland, and the UK. The study used an active comparator, new user design and included propensity score-matched adults with T2D initiating empagliflozin or a DPP-4i between 2014 and 2020 (2021 for the UK). Follow-upstarted at the index date (first prescription or dispensation for empagliflozin or a DPP-4i) and 180 days were considered as the latency period.  \nIncidence rates (IRs) and hazard ratios (HRs) were estimated under an as-treated approach in each country. HRs were then entered into a random-effects meta-analysis. Results: The main analyses included 151 055 matched people. The mean age forempagliflozin initiators was 57.0–63.2 years across the countries, and most were female (59 . 6%–67 .8%) . A meta-analysis of country-level HR showed no evidence of an increased risk of UTC (adjusted HR = 0.88, 95% confidence intervals [CIs]: 0 .66– 1. 17), bladder cancer (adjusted HR = 0.91, 95% CI: 0 .63–1.33) or renal cancer (adjusted HR = 0.89, 95% CI: 0 .57–1.38) for empagliflozin initiators compared with DPP-4i initiators. Various sensitivity analyses also validated the robustness of the main findings.  \nConclusions: No increased risk of UTC, bladder, and renal cancer was observed when empagliflozin initiators were compared with DPP-4i initiators in this noninterventional cohort study.  \nKEYWOR DS  \nbladder cancer, CPRD, diabetes type 2, DPP-4 inhibitor, epidemiology, meta-analysis, nordic countries, renal cancer, SGLT2i, urinary tract cancer  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.  \nDiabetes Obes Metab. 2025;27:4401–[4414.](4414. wileyonlinelibrary.com/journal/dom)[ wileyonlinelibrary.com/journal/dom](4414. wileyonlinelibrary.com/journal/dom)  4401  \n1 | INTRODUCTION  \nDiabetes is affecting an increasing number of people globally.1 According to the 2021 International Diabetes Federation estimates, the number of people with diabetes in Europe will rise from an estimated 61 million in 2021 to 69 million by 2045 .2  \nEmpagliflozin, a selective sodium-glucose co-transporter-2 inhibitor (SGLT2i), was approved in the European Union, including the United Kingdom (UK), in 2014 for the treatment of type 2 diabetes (T2D) to improve glycaemic control in adults by reducing renal glucose reabsorption.3  \nUrinary tract cancers (UTCs) were included as a potential risk atthe time of the initial approval in 2014 in the Risk Management Plan (RMP) for Jardiance® (empagliflozin) and Synjardy® (empagliflozin/ metformin hydrochloride) . This was based on preclinical toxicology findings and clinical cases obse","cbCair2zyxQbzqU1","https://ap.wps.com/l/cbCair2zyxQbzqU1","pdf",1572788,14,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Study design","[{\"question\":\"What was the primary objective of the post-authorisation safety study?\",\"answer\":\"To assess whether people with type 2 diabetes initiating empagliflozin had a different risk of urinary tract cancers, including bladder and renal cancers, compared with those initiating any DPP-4 inhibitor in the UK, Sweden, and Finland.\"},{\"question\":\"How was the study designed and what data sources were used?\",\"answer\":\"It was a non-interventional, multi-country cohort PASS using secondary data: CPRD in the UK and nationwide registers in Sweden and Finland, with an active comparator and a new user design using propensity score matching.\"},{\"question\":\"What were the main findings regarding cancer risk?\",\"answer\":\"The meta-analysis showed no evidence of increased risk of urinary tract cancer, bladder cancer, or renal cancer for empagliflozin initiators versus DPP-4 inhibitor initiators, and sensitivity analyses validated the robustness of these findings.\"}]","Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin - A multi-country European study | PDF",1790183805,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0aee075ea8ff1d12692c6bfb363a3263.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a22c183efb33d52421247c386a6d57cf.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8e251655fcf99c7a7da60591edf78f0.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24232fe34e6ba53264a5ef4a8344577b.webp",980,1287]